FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT04139057: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC |
|
|
| Recruiting | 1/2 | 18 | RoW | EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Xinqiao Hospital of Chongqing, TCRCure Biopharma Ltd. | Head and Neck Squamous Cell Carcinoma | 12/24 | 12/24 | | |
NCT06239298: A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 130 | RoW | ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor | 03/26 | 05/26 | | |
DEX, NCT05249153: Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery |
|
|
| Active, not recruiting | N/A | 84 | RoW | low dose of dexmedetomidine with sufentanil, Sufen with low DEX, high dose of dexmedetomidine with sufentanil, Sufen with high DEX | Peking Union Medical College Hospital | Dexmedetomidine | 12/25 | 12/25 | | |
| Terminated | N/A | 13 | RoW | | GeneCast Biotechnology Co., Ltd., Xinqiao Hospital of Chongqing, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Wuhan University, Renmin Hospital of Wuhan University, Tongji Hospital, Southwest Hospital, China, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, People's Hospital of Chongqing, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Wenzhou Medical University, The Affiliated Hospital Of Southwest Medical University, Guizhou Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Shanxi Provincial Cancer Hospital, First Hospital of China Medical University, Fujian Provincial Hospital, Peking University Shenzhen Hospital, Affiliated Cancer Hospital of Shantou University Medical College, The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Non-small Cell Lung Cancer, Neoantigen, Next-generation Sequencing, Biomarker | 12/21 | 12/21 | | |
